DURECT Corporation today reported that Takeda has given notice that it is returning its development and commercialization rights to POSIDUR in Europe and their other licensed territories.

Historic legal rulings did not protect the rights of persons with disabilities, while legal rulings concerned with race or gender provided much more protection of individual rights and freedoms according to the Canadian Charter of Rights and Freedoms Queen's University PhD student Christopher A. Riddle has determined in a recent ...

Historic legal rulings did not protect the rights of persons with disabilities, while legal rulings concerned with race or gender provided much more protection of individual rights and freedoms according to the Canadian Charter of Rights and Freedoms Queen's University PhD student Christopher A. Riddle has determined in a recent ...

(Queen's University) Historic legal rulings did not protect the rights of persons with disabilities, while legal rulings concerned with race or gender provided much more protection of individual rights and freedoms according to the Canadian Charter of Rights and Freedoms Queen's University Ph.D. student Christopher A. Riddle has determined in ...

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V. Terms of the agreement have not been disclosed.

Across Africa, "lesbian, gay, bisexual and transgender people suffer brutal attacks, yet cannot report them to the police for fear of additional violence, humiliation, rape or imprisonment at the hands of the authorities.

"The Obama administration said Tuesday that it will intensify efforts to fight discrimination against lesbians, gay men, bisexuals and transgender people as a major element of its foreign policy," the Washington Post reports.

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

Serious global discussions have begun in the lead-up to the Millennium Development Goal (MDG) deadline of 2015. Governments and international agencies are asking what has been achieved, what still needs to be done and how best to proceed after the deadline. Against this backdrop, a new paper published in the ...

Serious global discussions have begun in the lead-up to the Millennium Development Goal (MDG) deadline of 2015. Governments and international agencies are asking what has been achieved, what still needs to be done and how best to proceed after the deadline. Against this backdrop, a new paper published in the ...

London, November 28, 2011 - Serious global discussions have begun in the lead-up to the Millennium Development Goal (MDG) deadline of 2015. Governments and international agencies are asking what has been achieved, what still needs to be done and how best to proceed after the deadline. Against this backdrop, a ...